Evaluate the patient care recommandation induced by the IMMUNOSCORE® result
age between 18 and 80 inclusive;
histologically confirmed colon adenocarcinoma;
having undergone a curative resection of stage I, II or III colorectal cancer;
diagnosed T1 / T2 / T3 / T4 and N0 / N1 / N2;
pregnant or breastfeeding women
legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study.
history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled
person subject to a safeguard measure.
Single group
IMMUNOSCORE®
Diagnostic testrecommendation for patient care according to the result of the IMMUNOSCORE®
Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision
Replication error (RER) phenotype
Number of cases where the Immunoscore® resultat is inconsistent with the RER phenotype
KRAS, NRAS and BRAF mutations
Number of cases where the Immunoscore® resultat is inconsistent with the KRAS, NRAS and BRAF mutations
Ratio of ciruclating tumor DNA level
Number of cases where the Immunoscore® resultat is inconsistent with the ratio of ciruclating tumor DNA level
Actual survival (patient alive without recurrence, alive with recurrence, dead)
Number of cases where the Immunoscore® resultat is inconsistent with the actual survival
Click on the lead sponsor to view all of their trials.
